Fertility Partners sells Illume Fertility to IVI RMA

The Fertility Partners, Canada's largest network of fertility clinics, has announced the completion of the sale of Illume Fertility to IVI RMA North America, a move aimed at accelerating strategic growth and investment within its Canadian network.

The transaction, which closed on September 3, 2026, marks a deliberate portfolio decision by The Fertility Partners (TFP) to focus its capital, resources, and leadership attention on fostering growth opportunities within Canada. Illume Fertility, a prominent fertility practice serving patients in Connecticut and New York, has now become part of IVI RMA North America's expanding network of reproductive medicine providers.

Heather Stark, CEO of TFP, highlighted the strategic importance of this decision. "Illume has built a strong reputation for clinical excellence and genuine patient care," Stark said. "We are proud of the accomplishments of the Illume team and confident that IVI RMA is the right home for their continued success. For TFP, this transaction allows us to fully concentrate on building the leading fertility network in Canada."

The seamless transition was supported by close collaboration between TFP, Illume, and IVI RMA throughout the closing process, ensuring continuity for patients, physicians, employees, and partners. Stark emphasized, "We see significant opportunity ahead for TFP and the patients and communities we serve. We will continue to invest in the capabilities, infrastructure, and technology that will strengthen access, improve clinical outcomes, and support the long-term evolution of fertility care in Canada."

TFP remains committed to advancing patient-centred fertility care through clinical excellence, collaboration, and innovation. The company brings together leading fertility clinics and IVF laboratories across Canada, leveraging shared expertise, technology, and scale to enhance patient access to care and improve reproductive outcomes.

"We are excited about the future," Stark concluded. "This transaction is a testament to our commitment to growth and quality in Canada's fertility landscape."

TFP's dedication to clinical quality, operational excellence, and patient experience is underscored by its long-term commitment to advancing reproductive medicine in Canada. As the company moves forward, it aims to continue investing in the latest technologies and best practices to support patients and their families.

IVI RMA North America, a part of the world's leading Reproductive Medicine group, is committed to providing evidence-based fertility solutions. The transaction positions TFP to further strengthen its position as a leader in Canadian fertility care, ensuring continued access to high-quality reproductive services for patients across the country.